research Turning JAK STATic, a peek into the future of dermatology therapeutics
JAK inhibitors show promise for treating skin diseases effectively and safely.
Search
for
Sort by
Research
90-120 / 535 results 
research Alopecia areata: medical treatments
Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.
research JAK-centric explainable few-shot gene-expression diagnosis framework for alopecia via MultiPLIER priors and relation-style set-to-set comparison
A new method helps diagnose alopecia areata using specific gene markers and could guide targeted treatments.
research Transcriptome Dynamics Reveal Stage-Specific and Melatonin-Triggered Gene Expression Patterns During The Cashmere Growth Cycle in Capra Hircus
Melatonin affects certain genes and pathways involved in cashmere goat hair growth.
research Transcriptome Dynamics Reveal Stage-specific and Melatonin-triggered Gene Expression Patterns During the Cashmere Growth Cycle in Capra Hircus
Melatonin can increase cashmere yield by altering gene expression and restarting the growth cycle early.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research 915 Dietary grape powder inhibits atopic dermatitis-like skin lesions in NC/Nga mice
Eating grape powder may reduce the severity of skin allergy symptoms.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research MSC-EVs and UCB-EVs promote skin wound healing and spatial transcriptome analysis
MSC-EVs and UCB-EVs improve skin wound healing and reduce scarring.
research 691 Topical curcumin promotes induction of the murine hair cycle
Curcumin applied to the skin can start hair growth in mice.
research Pharmacotherapy of alopecia areata
JAK inhibitors and combination therapies show promise for treating severe alopecia areata.
research mTOR signaling in hair follicle and hair diseases: recent progress
The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.
research Novel TMEM173 Mutation and the Role of Disease Modifying Alleles
A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.
research Characterization of novel TMEM173 mutation with additive IFIH1 risk allele
A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.
research JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
research AP-2α/AP-2β transcription factors are key regulators of epidermal homeostasis
AP-2α and AP-2β proteins are essential for healthy adult skin and hair.
research Janus kinase inhibitors for alopecia areata: a review of clinical data
JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
research Alopecia areata: a comprehensive review of clinical, immunologic, and genetic perspectives
Alopecia Areata is an autoimmune disease causing hair loss, with no cure yet, but research may lead to new treatments.
research JAK inhibitors in dermatology: The promise of a new drug class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
research Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
Ritlecitinib is an effective new treatment for Alopecia Areata.
research 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
OR-101 shows promise for treating alopecia areata by improving hair growth.
research In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
Quercetin and kaempferol may be effective and safe natural treatments for hair loss.
research In Silico Structure-Based Drug Design Approach To Evaluate Quercetin And Kaempferol As Dual Inhibitors Of Jak3 Kinase And 5-Alpha Reductase Type II with ADMET Profiling
Quercetin and kaempferol may be effective and safe natural treatments for hair loss.
research A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
research Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
JAK inhibitors show promise for treating alopecia areata but have serious side effects.
research Dermal T cell immunity and key regulatory signaling pathways: Implications in immune-mediated alopecia and hair regeneration
Understanding T cells and signaling pathways can lead to better treatments for hair loss.
research ROS-responsive hydrogel-delivered miR-665 targets STAT3 to alleviate inflammation and promote hair follicle regeneration in alopecia areata
A new treatment using a special gel with miR-665 reduces inflammation and helps hair regrow in alopecia areata.
research Theoretical investigation on the construction of hair follicle membranes and the transdermal drug delivery mechanisms of JAK inhibitors via distinct pathways
JAK inhibitors can enter the skin through hair follicles using a unique pathway.
research Astilbin Activates the Reactive Oxidative Species/PPARγ Pathway to Suppress Effector CD4+ T Cell Activities via Direct Binding With Cytochrome P450 1B1
Astilbin can potentially calm overactive immune responses, like in Type 1 Diabetes, by suppressing certain cell activities and reducing inflammation.